Moreover, PAFAH1B3 loss in vivo sensitized leukemia cells to tyrosine kinase inhibitor (TKI) treatment via the platelet activating factor (PAF)/platelet activating factor receptor (PAFR) signaling pathway, and PAF/PAFR has been found to exhibit beneficial effects in some cancers [7, 12]. This evidence concerns the gene PAFAH1B3 and cancer.